EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY 4.0

Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies

Amanda J Sheets, Jeremy Dennison iD, Jason M Pogue, Keith S Kaye iD, Caroline Perry iD, Helen Millns, Jazmín Díaz-Regañón iD, Salim Janmohamed

Clinical Infectious Diseases · 2026

DOI: 10.1093/cid/ciaf722 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Clinical Infectious Diseases, 2026. Verfasst von Amanda J Sheets und 7 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Collegeville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Acenaphthenes, Anti-Bacterial Agents, Anti-Infective Agents, Urinary, Nitrofurantoin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK, US Department of Health and Human Services, Administration for Strategic Preparedness and Response.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Uncomplicated urinary tract infections (uUTIs) can cause distressing symptoms seriously impacting daily activities. Early symptom relief during treatment, though fundamental to patients, is often overlooked in clinical trials. Gepotidacin, a new antibacterial agent, was noninferior to the first-line treatment nitrofurantoin in two randomized controlled trials (EAGLE-2 [NCT04020341] and EAGLE-3 [NCT04187144]). The current analysis utilized pooled data from these two trials to evaluate symptom responses during and after treatment in participants with uUTI.

Methods

Participants were aged ≥12 years with at least two uUTI symptoms, urinary nitrite and/or pyuria, and no complicating factors. Participants were randomized 1:1 to oral gepotidacin (1500 mg) or nitrofurantoin (100 mg), both taken twice daily for 5 days. At baseline (Day 1), on-therapy (OT; Days 2–4), and test-of-cure (TOC; Days 10–13) visits, urinary symptoms were assessed (0–3; none–severe) from which a total score (0–12) was derived.

Results

Overall, 3136 participants were randomized (1572 gepotidacin, 1564 nitrofurantoin). Mean (median) baseline symptom scores for gepotidacin and nitrofurantoin arms were 7.1 (7.0) and 7.2 (7.0), respectively; at OT, this decreased to 3.6 (3.0) for both arms. At the OT visit, >80% of participants had clinical improvement/resolution. Among those with baseline symptoms affecting everyday activities (moderate or severe), 53.2% (728/1369) assigned gepotidacin and 53.6% (738/1377) assigned nitrofurantoin reported at OT that symptoms no longer affected everyday activities (mild or absent); at TOC, these percentages were 93.8% (1232/1313) and 93.3% (1254/1344), respectively.

Conclusions

Gepotidacin and nitrofurantoin provide meaningful and similar early relief from uUTI symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcenaphthenesAnti-Bacterial AgentsAnti-Infective Agents, UrinaryNitrofurantoinUrinary Tract InfectionsAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedYoung AdultTreatment OutcomeHeterocyclic Compounds, 3-Ring

Stichwörter der Autor:innen

antibacterialsgepotidacinuncomplicated UTIurinary tract infection

Substanzen

AcenaphthenesAnti-Bacterial AgentsAnti-Infective Agents, UrinarygepotidacinNitrofurantoinHeterocyclic Compounds, 3-Ring

Autor:innen und Institutionen

  • GSK, Collegeville, Pennsylvania, USA.
  • GSK, London, United Kingdom.
  • College of Pharmacy, University of Michigan, Ann Arbor, Michigan, USA.
  • Division of Allergy, Immunology and Infectious Diseases, and Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
  • GSK, Stevenage, United Kingdom.
  • GSK, Madrid, Spain.

ORCID-Profile: Jeremy Dennison, Keith S Kaye, Caroline Perry, Jazmín Díaz-Regañón

Förderung

  • GSK
  • US Department of Health and Human Services
  • Administration for Strategic Preparedness and Response
  • Biomedical Advanced Research and Development Authority

Zitieren

APA

Sheets, A. J., Dennison, J., Pogue, J. M., Kaye, K. S., Perry, C., Millns, H., Díaz-Regañón, J., & Janmohamed, S. (2026). Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf722

Vancouver

Sheets AJ, Dennison J, Pogue JM, Kaye KS, Perry C, Millns H, et al. Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciaf722

BibTeX
@article{Sheets2026,
  author = {Sheets, Amanda J and Dennison, Jeremy and Pogue, Jason M and Kaye, Keith S and Perry, Caroline and Millns, Helen and Díaz-Regañón, Jazmín and Janmohamed, Salim},
  title = {Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  doi = {10.1093/cid/ciaf722}
}
Kostenlos starten →